GlassScriptPhysician profile
Abhijit A Kulkarni
NPI 1609877521
$5,401.27
in general payments reported to CMS, 2019-2025
19 companies · $42.81 in 2025
The $42.81 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,779 · 2020: $1,500 · 2021: $516 · 2022: $187 · 2023: $163 · 2024: $213 · 2025: $42.81.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $419.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $419.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,189.08 | 2019-2024 | |
| Pinnacle Biologics, INC | $500.00 | 2021 | |
| Phathom Pharmaceuticals, INC. | $138.51 | 2024-2025 | Voquezna |
| Boston Scientific Corporation | $113.29 | 2019-2024 | Spyglass, Cre Pro |
| Medtronic, INC. | $111.77 | 2022 | |
| Ethicon US, LLC | $83.55 | 2019 | |
| Sandoz INC. | $41.80 | 2023 | Hyrimoz |
| Cook Medical LLC | $30.48 | 2022 | |
| Amgen INC. | $29.80 | 2023 | Avsola, Amjevita |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.29 | 2023 | Xifaxan |
| Nestle Healthcare Nutrition INC. | $21.01 | 2023 | |
| Madrigal Pharmaceuticals | $18.60 | 2025 | Rezdiffra |
| Genzyme Corporation | $15.82 | 2022 | |
| Conmed Corporation | $15.82 | 2021 | |
| Apollo Endosurgery US INC | $15.70 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $14.35 | 2019 | |
| Olympus America INC. | $13.64 | 2024 | Endoclot Phs |
| Aimmune Therapeutics, INC. | $13.47 | 2024 | |
| Redhill Biopharma INC. | $13.29 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abhijit Kulkarni listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.